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Mutations in the breast cancer susceptibility genes,
BRCA1 and BRCA2, represent the majority of the known
familial breast cancer risk, yet account for only 20% of the
total risk. As BRCA1 is a large gene, genetic screening of
high-risk individuals is limited to the coding regions and
intron-exon boundaries, which precludes the identification
of mutations in non-coding and untranslated (UTR)
regions. Although mutations within 3’UTRs have been
identified in many genes and are known to influence can-
cer susceptibility through the disruption or creation of
protein and microRNA binding regions, mutation analysis
of the BRCA1 3’UTR to date has been very limited. In this
study, we screened the BRCA1 3’UTR for potential regula-
tory mutations. Using a large cohort of 1,585 BRCA-muta-
tion negative, breast cancer cases, we identified seventeen
novel BRCA1 3’UTR variants, eight of which were identi-
fied in breast cancer cases and absent in a large panel of
cancer-free controls. Four of these variants, c.*58C>T, c.
*528G>C, c.*718A>G, and c.*1271T>C, significantly
reduced 3’UTR associated regulatory activity, as measured
by reporter assays using MDA-MB-231 breast cancer cells.
In addition, three BRCA1 3’UTR variants, c.*718A>G, c.
*800T>C and c.*1340_42TGTdel, were predicted to create
new miRNA binding sites. Of these, c.*1340_42TGTdel
showed a significant reduction (25%, p=0.0007) in lucifer-
ase activity when co-expressed with the predicted targeting
miRNA, miR-103 in MCF-7 cells. This is the most com-
prehensive set of BRCA1 3’UTR variants published to date
and highlights the importance of cataloguing 3’UTR
variants for functional analyses and cancer risk association.
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